Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from YB-1 Inhibition Suppresses Osteosarcoma Growth and Reverses Tumor Immunosuppression. Local targets link to admitted publications; unresolved targets remain external evidence.
The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity
10.1056/nejm198606193142502 · 1986 · External reference
Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 good response randomized controlled trial
10.1200/jco.2014.60.0734 · 2015 · External reference
Osteosarcoma, chondrosarcoma, and chordoma
10.1200/jco.2017.75.1743 · 2018 · External reference
Changing pattern of relapse in osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy
10.1179/joc.1995.7.3.230 · 1995 · External reference
Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS)
10.1200/jco.2005.04.063 · 2005 · External reference
Outcome of patients with recurrent osteosarcoma enrolled in seven phase II trials through Children’s Cancer Group, Pediatric Oncology Group, and Children’s Oncology Group: learning from the past to move forward
10.1200/jco.2015.65.5381 · 2016 · External reference
Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone
10.1186/s12885-016-2312-3 · 2016 · External reference
A meta-analysis of osteosarcoma outcomes in the modern medical era
10.1155/2012/704872 · 2012 · External reference
A decade of immune-checkpoint inhibitors in cancer therapy
10.1038/s41467-020-17670-y · 2020 · External reference
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
10.1007/s00262-021-02876-w · 2021 · External reference
Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study
10.1016/j.ejca.2019.07.018 · 2019 · External reference
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
10.1016/s1470-2045(17)30624-1 · 2017 · External reference
The clinical implications of tumor mutational burden in osteosarcoma
10.3389/fonc.2020.595527 · 2020 · External reference
RNA-binding proteins and cancer metastasis
10.1016/j.semcancer.2022.03.018 · 2022 · External reference
Cold shock proteins: from cellular mechanisms to pathophysiology and disease
10.1186/s12964-018-0274-6 · 2018 · External reference
Y-box-binding protein 1 (YB-1) and its functions
10.1134/s0006297911130049 · 2011 · External reference
Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition
10.1016/j.ccr.2009.03.017 · 2009 · External reference
Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway
10.1038/s41388-018-0222-3 · 2018 · External reference
Targeting the YB-1/PD-L1 axis to enhance chemotherapy and antitumor immunity
10.1158/2326-6066.cir-18-0648 · 2019 · External reference
YB-1 promotes cell proliferation and metastasis by targeting cell-intrinsic PD-1/PD-L1 pathway in breast cancer
10.1016/j.biocel.2022.106314 · 2022 · External reference
Translational activation of HIF1α by YB-1 promotes sarcoma metastasis
10.1016/j.ccell.2015.04.003 · 2015 · External reference
Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma
10.1038/bjc.2012.579 · 2013 · External reference
Inhibition of protein translational machinery in triple-negative breast cancer as a promising therapeutic strategy
10.1016/j.xcrm.2024.101552 · 2024 · External reference
Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer
10.1016/j.chembiol.2021.02.014 · 2021 · External reference
Trabectedin overrides osteosarcoma differentiative block and reprograms the tumor immune environment enabling effective combination with immune checkpoint inhibitors
10.1158/1078-0432.ccr-16-3186 · 2017 · External reference
Integration of genomic, transcriptomic and functional profiles of aggressive osteosarcomas across multiple species
10.18632/oncotarget.19532 · 2017 · External reference
Drug combination studies and their synergy quantification using the Chou-Talalay method
10.1158/0008-5472.can-09-1947 · 2010 · External reference
Whole transcriptome analysis identifies differentially regulated networks between osteosarcoma and normal bone samples
10.1177/1535370217736512 · 2017 · External reference
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
10.1186/s13059-014-0550-8 · 2014 · External reference
Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors
2024 · External reference
The pyruvate dehydrogenase complex in concert with the DNA/RNA-binding protein YBX1 regulates cell senescence and tumorigenesis
10.1016/j.jbc.2025.110585 · 2025 · External reference
A gene set enrichment analysis for cancer hallmarks
10.1016/j.jpha.2024.101065 · 2025 · External reference
Doxorubicin-induced cardiotoxicity is mediated by neutrophils through release of neutrophil elastase
10.3389/fonc.2022.947604 · 2022 · External reference
Clinical relevance of tumour-associated macrophages
10.1038/s41571-022-00620-6 · 2022 · External reference
RAN and YBX1 are required for cell proliferation and IL-4 expression and linked to poor prognosis in oral squamous cell carcinoma
10.1016/j.yexcr.2021.112767 · 2021 · External reference
Nucleolin and YB-1 are required for JNK-mediated interleukin-2 mRNA stabilization during T-cell activation
10.1101/gad.14.10.1236 · 2000 · External reference
Harnessing IL-2 for immunotherapy against cancer and chronic infection: a historical perspective and emerging trends
10.1038/s12276-024-01301-3 · 2024 · External reference
HIF-1α inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer
10.1016/j.canlet.2022.01.027 · 2022 · External reference
Hypoxia-driven M2-polarized macrophages facilitate cancer aggressiveness and temozolomide resistance in glioblastoma
10.1155/2022/1614336 · 2022 · External reference
Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial
10.1001/jamaoncol.2017.1617 · 2018 · External reference
